Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses

Journal of Medicinal Chemistry

Volumn 53, Issue 17, 2010, Pages 6421-6431

  Oakley, Aaron J ^a,b   Barrett, Susan ^a   Peat, Thomas S ^a   Newman, Janet ^a   Streltsov, Victor A ^a   Waddington, Lynne ^a   Saito, Takehiko ^c,d   Tashiro, Masato ^c   McKimm Breschkin, Jennifer L ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 KETO 3 DEOXY DEXTRO GLYCERO DEXTRO GALACTONONULOSONIC ACID; ANTIVIRUS AGENT; OSELTAMIVIR; PERAMIVIR; SIALIC ACID; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG PROTEIN BINDING; ELECTRON MICROSCOPY; ENZYME STRUCTURE; INFLUENZA VIRUS B; NONHUMAN; PROTEIN FUNCTION; PROTEIN PURIFICATION; VIRUS MUTATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; GUANIDINES; HYDROGEN BONDING; INFLUENZA B VIRUS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PROTEIN BINDING; ZANAMIVIR;

EID: 77956313833     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100621s     Document Type: Article

References (57)

1. Varghese, J. N.; Laver, W. G.; Colman, P. M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution Nature 1983, 303, 35-40
2. Colman, P. M.; Varghese, J. N.; Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 1983, 303, 41-44
3. Burmeister, W. P.; Daniels, R. S.; Dayan, S.; Gagnon, J.; Cusack, S.; Ruigrok, R. W. Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase Virology 1991, 180, 266-272
4. Burmeister, W. P.; Ruigrok, R. W.; Cusack, S. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid EMBO J. 1992, 11, 49-56
5. Janakiraman, M. N.; White, C. L.; Laver, W. G.; Air, G. M.; Luo, M. Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8-Å resolution: implications for the catalytic mechanism Biochemistry (Moscow) 1994, 33, 8172-8179
6. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 1993, 363, 418-423
7. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen., M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site:design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J. Am. Chem. Soc. 1997, 119, 681-690
8. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T. H.; Hutchison, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design J. Med. Chem. 2000, 43, 3482-3486
9. BioCryst Peramivir (Neuraminidase Inhibitor). http://www.biocryst.com/ peramivir.htm (accessed March 10, 2009).
10. Gubareva, L. V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors Virus Res. 2004, 103, 199-203
11. de Jong, M. D.; Tran, T. T.; Truong, H. K.; Vo, M. H.; Smith, G. J.; Nguyen, V. C.; Bach, V. C.; Phan, T. Q.; Do, Q. H.; Guan, Y.; Peiris, J. S.; Tran, T. H.; Farrar, J. Oseltamivir resistance during treatment of influenza A (H5N1) infection N. Engl. J. Med. 2005, 353, 2667-2672
12. Ward, P.; Small, I.; Smith, J.; Suter, P.; Dutkowski, R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic J. Antimicrob. Chemother. 2005, 55 (Suppl. 1) i5-i21
13. Hatakeyama, S.; Sugaya, N.; Ito, M.; Yamazaki, M.; Ichikawa, M.; Kimura, K.; Kiso, M.; Shimizu, H.; Kawakami, C.; Koike, K.; Mitamura, K.; Kawaoka, Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors JAMA, J. Am. Med. Assoc. 2007, 297, 1435-1442
14. Stephenson, I.; Democratis, J.; Lackenby, A.; McNally, T.; Smith, J.; Pareek, M.; Ellis, J.; Bermingham, A.; Nicholson, K.; Zambon, M. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children Clin. Infect. Dis. 2009, 48, 289-296
15. Hurt, A. C.; Ernest, J.; Deng, Y. M.; Iannello, P.; Besselaar, T. G.; Birch, C.; Buchy, P.; Chittaganpitch, M.; Chiu, S. C.; Dwyer, D.; Guigon, A.; Harrower, B.; Kei, I. P.; Kok, T.; Lin, C.; McPhie, K.; Mohd, A.; Olveda, R.; Panayotou, T.; Rawlinson, W.; Scott, L.; Smith, D.; D'souza, H.; Komadina, N.; Shaw, R.; Kelso, A.; Barr, I. G. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa Antiviral Res. 2009, 83, 90-93
16. Meijer, A.; Lackenby, A.; Hungnes, O.; Lina, B.; van-der-Werf, S.; Schweiger, B.; Opp, M.; Paget, J.; van-de-Kassteele, J.; Hay, A.; Zambon, M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season Emerging Infect. Dis. 2009, 15, 552-560
17. Wang, B.; Dwyer, D. E.; Blyth, C. C.; Soedjono, M.; Shi, H.; Kesson, A.; Ratnamohan, M.; McPhie, K.; Cunningham, A. L.; Saksena, N. K. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections Antiviral Res. 2010, 87, 16-21
18. Le, Q. M.; Wertheim, H. F.; Tran, N. D.; van Doorn, H. R.; Nguyen, T. H.; Horby, P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza N. Engl. J. Med. 2010, 362, 86-87
19. Gubareva, L. V.; Matrosovich, M. N.; Brenner, M. K.; Bethell, R. C.; Webster, R. G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus J. Infect. Dis. 1998, 178, 1257-1262
20. Hurt, A. C.; Iannello, P.; Jachno, K.; Komadina, N.; Hampson, A. W.; Barr, I. G.; McKimm-Breschkin, J. L. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient Antimicrob. Agents Chemother. 2006, 50, 1872-1874
21. Sugaya, N.; Mitamura, K.; Yamazaki, M.; Tamura, D.; Ichikawa, M.; Kimura, K.; Kawakami, C.; Kiso, M.; Ito, M.; Hatakeyama, S.; Kawaoka, Y. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children Clin. Infect. Dis. 2007, 44, 197-202
22. Sugaya, N.; Tamura, D.; Yamazaki, M.; Ichikawa, M.; Kawakami, C.; Kawaoka, Y.; Mitamura, K. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children Clin. Infect. Dis. 2008, 47, 339-345
23. Burmeister, W. P.; Baudin, F.; Cusack, S.; Ruigrok, R. W. Comparison of structure and sequence of influenza B/Yamagata and B/Beijing neuraminidases shows a conserved "head" but much greater variability in the "stalk" and NB protein Virology 1993, 192, 683-686
24. Sahasrabudhe, A.; Lawrence, L.; Epa, V. C.; Varghese, J. N.; Colman, P. M.; McKimm-Breschkin, J. L. Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase Virology 1998, 247, 14-21
25. Hurt, A. C.; McKimm-Breschkin, J. L.; McDonald, M.; Barr, I. G.; Komadina, N.; Hampson, A. W. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs Virus Res. 2004, 103, 205-211
26. Tashiro, M.; McKimm-Breschkin, J. L.; Saito, T.; Klimov, A.; Macken, C.; Zambon, M.; Hayden, F. G. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007 Antiviral Ther. 2009, 14, 751-761
27. Blick, T. J.; Tiong, T.; Sahasrabudhe, A.; Varghese, J. N.; Colman, P. M.; Hart, G. J.; Bethell, R. C.; McKimm-Breschkin, J. L. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en Virology 1995, 214, 475-484
28. McKimm-Breschkin, J. L.; Sahasrabudhe, A.; Blick, T. J.; McDonald, M.; Colman, P. M.; Hart, G. J.; Bethell, R. C.; Varghese, J. N. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors J. Virol. 1998, 72, 2456-2462
29. Baum, E. Z.; Wagaman, P. C.; Ly, L.; Turchi, I.; Le, J.; Bucher, D.; Bush, K. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding Antiviral Res. 2003, 59, 13-22
30. Kati, W. M.; Saldivar, A. S.; Mohamadi, F.; Sham, H. L.; Laver, W. G.; Kohlbrenner, W. E. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains Biochem. Biophys. Res. Commun. 1998, 244, 408-413
31. Kubelka, V.; Altmann, F.; Kornfeld, G.; Marz, L. Structures of the N-linked oligosaccharides of the membrane glycoproteins from three lepidopteran cell lines (Sf-21, IZD-Mb-0503, Bm-N) Arch. Biochem. Biophys. 1994, 308, 148-157
32. Taylor, N. R.; Cleasby, A.; Singh, O.; Skarzynski, T.; Wonacott, A. J.; Smith, P. W.; Sollis, S. L.; Howes, P. D.; Cherry, P. C.; Bethell, R.; Colman, P.; Varghese, J. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4 H -pyran-6-carboxamides and sialidase from influenza virus types A and B J. Med. Chem. 1998, 41, 798-807
33. Watts, A. G.; Oppezzo, P.; Withers, S. G.; Alzari, P. M.; Buschiazzo, A. Structural and kinetic analysis of two covalent sialosyl-enzyme intermediates on Trypanosoma rangeli sialidase J. Biol. Chem. 2006, 281, 4149-4155
34. Hart, G. J.; Bethell, R. C. 2,3-Didehydro-2,4-dideoxy-4-guanidino- N -acetyl- d -neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus Biochem. Mol. Biol. Int. 1995, 36, 695-703
35. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J.; Russell, R. J.; Walker, P. A.; Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants Nature 2008, 453, 1258-1261
36. Varghese, J. N.; Smith, P. W.; Sollis, S. L.; Blick, T. J.; Sahasrabudhe, A.; McKimm-Breschkin, J. L.; Colman, P. M. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase Structure 1998, 6, 735-746
37. Smith, B. J.; McKimm-Breschkin, J. L.; McDonald, M.; Fernley, R. T.; Varghese, J. N.; Colman, P. M. Structural studies of the resistance of influenza virus neuramindase to inhibitors J. Med. Chem. 2002, 45, 2207-2212
38. Wang, M. Z.; Tai, C. Y.; Mendel, D. B. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir Antimicrob. Agents Chemother. 2002, 46, 3809-3816
39. Pegg, M. S.; von Itzstein, M. Slow-binding inhibition of sialidase from influenza virus Biochem. Mol. Biol. Int. 1994, 32, 851-858
40. McKimm-Breschkin, J.; Trivedi, T.; Hampson, A.; Hay, A.; Klimov, A.; Tashiro, M.; Hayden, F.; Zambon, M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir Antimicrob. Agents Chemother. 2003, 47, 2264-2272
41. Cass, L. M.; Brown, J.; Pickford, M.; Fayinka, S.; Newman, S. P.; Johansson, C. J.; Bye, A. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers Clin. Pharmacokinet. 1999, 36 (Suppl. 1) 21-31
42. Oo, C.; Barrett, J.; Hill, G.; Mann, J.; Dorr, A.; Dutkowski, R.; Ward, P. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children Paediatr. Drugs 2001, 3, 229-236; erratum appears in Paediatr. Drugs 2001, 3 (4), 246
43. Wattanagoon, Y.; Stepniewska, K.; Lindegardh, N.; Pukrittayakamee, S.; Silachamroon, U.; Piyaphanee, W.; Singtoroj, T.; Hanpithakpong, W.; Davies, G.; Tarning, J.; Pongtavornpinyo, W.; Fukuda, C.; Singhasivanon, P.; Day, N. P.; White, N. J. Pharmacokinetics of high-dose oseltamivir in healthy volunteers Antimicrob. Agents Chemother. 2009, 53, 945-952
44. Morrison, D.; Roy, S.; Rayner, C.; Amer, A.; Howard, D.; Smith, J. R.; Evans, T. G. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination PLoS One 2007, 2 e1305
45. Lew, W.; Chen, X.; Kim, C. U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor Curr. Med. Chem. 2000, 7, 663-672
46. Neuraminidase Inhibitor Susceptibility Network (NISN). Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly. Epidemiol. Rec. 2007, 27, 149-150.
47. McKimm-Breschkin, J. L.; Caldwell, J. B.; Guthrie, R. E.; Kortt, A. A. A new method for the purification of the influenza A virus neuraminidase J. Virol. Methods 1991, 32, 121-124
48. Potier, M.; Mameli, L.; Belisle, M.; Dallaire, L.; Melancon, S. B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha- d-N -acetylneuraminate) substrate Anal. Biochem. 1979, 94, 287-296
49. McKimm-Breschkin, J. L.; Blick, T. J.; Sahasrabudhe, A.; Tiong, T.; Marshall, D.; Hart, G. J.; Bethell, R. C.; Penn, C. R. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en Antimicrob. Agents Chemother. 1996, 40, 40-46
50. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
51. McPhillips, T. M.; McPhillips, S. E.; Chiu, H. J.; Cohen, A. E.; Deacon, A. M.; Ellis, P. J.; Garman, E.; Gonzalez, A.; Sauter, N. K.; Phizackerley, R. P.; Soltis, S. M.; Kuhn, P. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines J. Synchrotron Radiat. 2002, 9, 401-406
52. Leslie, A. W. G. Recent changes to MOSFLM package for processing film and image plate data. Joint CCP4 ESF-EAMCB Newslett. Protein Crystallogr. 1992, 26.
53. Evans, P. Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 72-82
54. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948-1954
55. Vagin, A.; Teplyakov, A. MOLREP:an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025
56. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
57. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255